Diagnostics Reform Reintroduced in House
Executive Summary
The VALID Act, which will hand diagnostics oversight to the US FDA, has been reintroduced in the House of Representatives after it failed twice last year in Congress.
You may also be interested in...
Congress Revives Talks On LDTs With Clock Ticking On FDA Rule
During a recent hearing of the US House Energy and Commerce Health Subcommittee, lawmakers discussed the best approach to regulating laboratory developed tests (LDTs) with a panel of experts representing clinical labs. At issue was the FDA’s proposed rule that places LDTs under the same regulatory purview as other in vitro diagnostics, which would require medical facilities to receive agency approval for the LDTs they develop in their own labs.
April Rule, Or April Fool? Will Final LDT Rule Be Ready On Time?
The White House has indicated that it expects the US FDA to publish its final rule on regulating lab-developed tests by April. But first, the agency must consider thousands of comments that have poured in since the proposal was published in October.
Hillebrenner Fields Questions On FDA’s Proposed Rule To Regulate LDTs, Says No To Extended Comment Period
During a recent webinar, Elizabeth Hillebrenner of the US FDA’s device center sought to clarify specifics on the agency’s proposed rule to regulate laboratory-developed tests, which establishes FDA oversight of the tests over a five-year period.